These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10719423)

  • 41. The chromogranin-secretogranin family.
    Scherübl H; Grabowski P
    N Engl J Med; 2003 Jun; 348(25):2579-80; author reply 2579-80. PubMed ID: 12815149
    [No Abstract]   [Full Text] [Related]  

  • 42. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
    Gofrit ON; Zorn KC; Taxy JB; Lin S; Zagaja GP; Steinberg GD; Shalhav AL
    J Urol; 2007 Nov; 178(5):1925-8. PubMed ID: 17868725
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Prostate specific antigen: utilization modalities and interpretation].
    Hannoun-Levi JM; Ginot A; Thariat J
    Cancer Radiother; 2008 Dec; 12(8):848-55. PubMed ID: 18539498
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
    Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
    Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Diagnostic value of tissue and serum prostate specific antigen in prostate cancer].
    Medvedev VL
    Voen Med Zh; 2004 Feb; 325(2):50-4. PubMed ID: 15101295
    [No Abstract]   [Full Text] [Related]  

  • 49. Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation.
    Michael A; Stephan C; Kristiansen G; Burckhardt M; Loening SA; Schnorr D; Jung K
    Prostate; 2005 Jan; 62(1):34-9. PubMed ID: 15389818
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.
    Quek ML; Daneshmand S; Rodrigo S; Cai J; Dorff TB; Groshen S; Skinner DG; Lieskovsky G; Pinski J
    Urology; 2006 Jun; 67(6):1247-52. PubMed ID: 16697447
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [A case of prostate cancer with invasion to the middle ureter].
    Matsuo T; Hayashida Y; Takehara K; Tsuda S; Furukawa M; Iwasaki S
    Hinyokika Kiyo; 2004 Jan; 50(1):61-3. PubMed ID: 15032020
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum calcitonin gene-related peptide levels in untreated prostate cancer patients.
    Suzuki K; Kobayashi Y; Morita T
    Int J Urol; 2006 Jun; 13(6):781-4. PubMed ID: 16834660
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer.
    Teloken C; Da Ros CT; Caraver F; Weber FA; Cavalheiro AP; Graziottin TM
    J Urol; 2005 Dec; 174(6):2178-80. PubMed ID: 16280759
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer.
    Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
    Urology; 2004 Mar; 63(3):492-8. PubMed ID: 15028444
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Clinical significance of histological types of prostatic cancer].
    Medvedev VL; Matsionis AE; Medvedeva LA
    Urologiia; 2003; (6):10-4. PubMed ID: 14708236
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum prostate-specific antigen: its use in diagnosis and management of prostate cancer.
    Lange PH; Brawer MK
    Urology; 1989 Jun; 33(6 Suppl):13-7. PubMed ID: 2471346
    [No Abstract]   [Full Text] [Related]  

  • 57. [Specific prostatic antigen: usefulness in clinical practice].
    Isa Kroon WA; Sánchez de la Muela PL; Berian Polo JM
    Med Clin (Barc); 1992 Mar; 98(9):345-7. PubMed ID: 1374824
    [No Abstract]   [Full Text] [Related]  

  • 58. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer.
    Schatzl G; Madersbacher S; Haitel A; Gsur A; Preyer M; Haidinger G; Gassner C; Ochsner M; Marberger M
    J Urol; 2003 Apr; 169(4):1312-5. PubMed ID: 12629350
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Small-cell neuroendocrine carcinoma as a variant form of prostate cancer recurrence: a case report and short literature review.
    Yashi M; Terauchi F; Nukui A; Ochi M; Yuzawa M; Hara Y; Morita T
    Urol Oncol; 2006; 24(4):313-7. PubMed ID: 16818183
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prostate specific antigen and other markers for prostate cancer.
    Schröder FH
    J Urol; 2006 Apr; 175(4):1199-200. PubMed ID: 16515959
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.